The Trump administration says it has now reached most-favored-nation pricing agreements with 26 pharmaceutical manufacturers, after nine more companies signed on in late August, together covering close to 90 percent of the branded drug market. The commitments promise reductions of 30 to 80 percent on drugs treating conditions from hemophilia to macular degeneration to certain cancers. But a signed agreement and a lower price at the pharmacy counter are two different things, and for most of the drugs covered by this latest round, the discount has not yet reached the register.
How The Count Reached Twenty-Six
The nine newest companies — Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB — are mid-sized manufacturers rather than the largest household-name drugmakers that signed earlier in the year. Their products treat hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, certain skin conditions, and several forms of cancer, according to the administration’s account of the agreements.
Each agreement commits the manufacturer to most-favored-nation pricing, meaning the U.S. price for a given drug should match the lowest price that manufacturer charges in other wealthy countries, on both existing products and any new medicine the company brings to market. The nine companies also pledged roughly $19.6 billion combined toward domestic manufacturing, and several agreed to donate raw pharmaceutical ingredients — including more than 160 tons of an anticonvulsant from one manufacturer and tens of tons of antibiotics from two others — to a federal strategic reserve intended to reduce reliance on foreign ingredient supplies.
With the nine new agreements added to the 17 companies that signed on earlier — a group that includes Pfizer, Eli Lilly, Novo Nordisk, Merck, and AstraZeneca — the administration counts 26 total manufacturers under MFN-aligned terms, together representing close to 90 percent of the branded prescription drug market by the administration’s own measure.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
Why The Discount Isn’t At The Register Yet
A most-favored-nation agreement is a commitment about a target price, not an announcement that a specific drug’s shelf price has already changed. The administration’s own fact sheet describes the reductions as something the agreements will “provide” rather than something that has already taken effect at pharmacies nationwide, and it does not list a rollout date for when patients taking one of the newly covered drugs would see the lower price reflected in what they pay.
Independent health-policy researchers have raised a related question about the broader MFN approach: whether a voluntary manufacturer agreement, without a legal enforcement mechanism tied to it, reliably translates into a lower price for an individual patient at checkout, or whether the benefit shows up more in list-price benchmarks and Medicaid access than in what a retiree pays out of pocket that week. KFF’s analysis of the administration’s broader drug-pricing executive order raises exactly that gap between a signed commitment and a measurable change in a patient’s bill.
The Council of Economic Advisers, a White House office, estimates the total savings from all the MFN deals combined could reach $600 billion over the next decade — a projection from the administration’s own economists, not an independently audited figure, and one that describes savings across the health system over ten years rather than a discount any single patient can expect this year.
What Is Actually Live Right Now
Separate from the newest nine deals, one piece of the broader MFN push is already operating and measurable: TrumpRx.gov, the federal portal the administration launched in February 2026 to connect patients with discounted prices from manufacturers that had already signed agreements. As of the administration’s late-August accounting, patients had saved more than $700 million through the portal since its launch.
The clearest example is a Medicare-linked program for GLP-1 weight-loss drugs that began July 1, 2026, letting seniors who lacked other coverage for those medicines pay $50 a month instead of list prices that can run over $1,000. In its first two months, more than 500,000 seniors used it and saved a combined $216 million, figures the administration has published as evidence the broader MFN strategy can move from a signed agreement to money a patient actually keeps.
The MFN agreements are also separate from Medicare’s own drug-price negotiation program, which sets government-negotiated prices for a specific list of medicines under different legal authority and a different timeline. A senior comparing what they pay for a specific prescription should check which program, if either, actually applies to that drug, since a manufacturer’s MFN commitment and a Medicare-negotiated price are not the same mechanism and do not take effect on the same schedule.
Whether the nine newest agreements follow that same path, and how quickly, is not yet answered in the record the administration has released. What is documented is the split between a deal that is signed and a price that has changed at the counter — and, for now, only a portion of the manufacturers under MFN terms have a live public channel, like TrumpRx, showing the second half of that promise.
What The Statement Never Shows
The manufacturer agreements above are aimed at list prices industry-wide, but a Medicare beneficiary’s own drug costs depend on a separate, already-active program: Extra Help, the low-income subsidy that can reduce or eliminate what a Part D enrollee pays in premiums, deductibles, and copays regardless of what any manufacturer commits to nationally. A monthly Medicare drug-plan statement shows what was billed and paid, not whether the enrollee already qualifies for that assistance.
The Benefits Checklist covers Extra Help alongside ten other programs across 69 pages, including the 2026 income limits that determine who qualifies.
Check whether a household already qualifies for Extra Help in The Benefits Checklist.
This article was researched and drafted with AI assistance and reviewed against primary sources before publication.
